initial public offerings (IPOs) trading on American exchanges

Thursday, October 21, 2021

TScan Therapeutics (TCRX) began trading on the Nasdaq on Fri 16 July 21

TScan Therapeutics (TCRX) has priced its IPO of ~6.7M shares of common stock at $15.00/share, for gross proceeds of $100M.
The company initially filed to offer 6.25M shares at a price range of $15-$17.

  • TScan is a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies (TCR-T) for the treatment of patients with cancer.
  • The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation.
  • TCRX is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
  • The company plans to submit IND applications for each of TSC-100 and TSC-101 with the FDA  in Q4 2021.

No comments:

Post a Comment